Petri Bio

Next-generation of therapeutics from gut microbes

https://wefunder.com/petribioold

Total raised on Wefunder: 107683

Total investors: 238

Quick facts

  • We develop therapeutics inspired by the data collected by animal and microbial genome projects.
  • Positioned to mine 32+ terabytes of genomic data for future drug precursors.
  • Founded by 2 PhD scientists (3 patents and 14 publications). 2nd-time founder (YCS17).
  • Patent-pending treatment for COVID-19 under evaluation by a pharma company for sponsorship.
  • Early pipeline of candidates help treat IBD, which affects 1.6M people and $15B market
  • Drug precursor for the treatment of NAFLD/NASH (“fatty liver disease”), $7B growing market.

Team profiles

Featured investor profiles

Petri Bio

Next-generation of therapeutics from gut microbes

Funded badge
Last Funded December 2020

$107,683

raised from 238 investors

What Investors Say

Entrepreneur
LEAD INVESTOR
Invested $1,000 this round
Shu and Joe are two all-star co-founders with deep technical expertise and prior startup expertise. By combining first-in-class comparative genomics and directed evolution, they have developed a library of therapeutic candidates for COVID-19 that neutralize the spike protein on SARS-CoV-2 and inhibit infection. Additionally, the peptide inhibitor can be functionally modified to prime the host’s immune system for response, cleverly doubling as both a therapeutic and immune-boosting combination, providing treatment throughout the entire course of disease progression. The team has computationally identified high-affinity drug candidates, partnered with a manufacturer, and is ready to initiate in vitro candidate evaluation. Finally, their platform can be repurposed for future uses besides biotherapeutics such as the agriculture and industrial biochemical markets.
What People Say